Novo Nordisk Faces Challenges Amid Capital Markets Day Insights
· gurufocus.com
Novo Nordisk (NVO) has experienced a significant decline following its Capital Markets Day, where it projected revenue growth from 2026 to 2030 that aligns with
Novo Nordisk NVO has experienced a significant decline following its Capital Markets Day, where it projected revenue growth from 2026 to 2030 that aligns with t...